A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT00096837 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2006-06-08
Summary
The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.
Conditions
Interventions
- DRUG
-
Motexafin Gadolinium Injection
Sponsors & Collaborators
-
Pharmacyclics LLC.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
NCT03731832 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03287908 ·Status: TERMINATED ·Phase: PHASE1
-
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
NCT03269136 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
NCT02046070 ·Status: COMPLETED ·Phase: PHASE2
-
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
NCT02294357 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT06126237 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
NCT01470131 ·Status: TERMINATED ·Phase: PHASE3
-
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
NCT03715478 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
NCT01301807 ·Status: COMPLETED ·Phase: PHASE1
-
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
NCT00833833 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT01832727 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma
NCT00241371 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia
NCT00360035 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
NCT02969837 ·Status: COMPLETED ·Phase: PHASE2
-
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
NCT01866293 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
NCT02568943 ·Status: NO_LONGER_AVAILABLE
-
CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
NCT00558896 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT06484829 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)
NCT00293111 ·Status: TERMINATED ·Phase: PHASE2
-
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
NCT07105059 ·Status: RECRUITING ·Phase: PHASE1
-
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
NCT02597062 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT06433947 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT01564537 ·Status: COMPLETED ·Phase: PHASE3